Dr. Daniel Wallace Appointed to Lupus Therapeutics Board
New York, NY, July 18, 2019 — The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel Wallace, MD joins as a new member of its Board of Directors. Including lupus patients, family members and scientists, this governing body provides strategic insight and financial oversight to help the organization achieve its mission – […]
Welcoming Daniel J. Wallace, MD to Lupus Therapeutics
The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel J. Wallace, MD joins as a new member of its distinguished Board of Directors. A renowned leader in clinical research and care for lupus and other rheumatologic diseases, Dr. Wallace is Medical Director of the Wallace Rheumatic Study Center and Associate […]
Organizational Structure
Lupus Therapeutics Board of Directors: Joseph Craft, MD is Paul B. Beeson Professor of Medicine and Professor of Immunobiology at the Yale School of Medicine, and past chief of the Section of Rheumatology at Yale. He received his degrees in chemistry as a Phi Beta Kappa graduate of University of North Carolina at Chapel Hill […]
Board of Directors
Lupus Therapeutics, Affiliate of Lupus Research Alliance, Developing a Study Focused on Lupus Patients and COVID-19
New York, NY, April 7, 2020 – Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance (LRA), announced today that it is embarking on a clinical study to assess the potential benefit of hydroxychloroquine and/or other lupus therapies in preventing or reducing the symptoms of COVID-19 in people with lupus. The study […]
Lupus Therapeutics, filial de Lupus Research Alliance, desarrolla un estudio que se enfoca en los pacientes con lupus y la COVID-19
7 de abril de 2020 Nueva York, NY, 7 de abril de 2020 – Lupus Therapeutics, la filial de ensayos clínicos de Lupus Research Alliance (LRA), anunció hoy que está iniciando un estudio clínico para evaluar el posible beneficio de la hidroxicloroquina u otras terapias para el lupus con el fin de evitar o […]
Lupus Research Update
Lupus Research Update Volume 3 | 2022 Lupus Research Update Volume 2 | 2022 Lupus Research Update Volume 1 | 2022 Lupus Research Update Volume 3 | 2021 Lupus Research Update Volume 2 |2021 COVID-19 Vaccines and the Lupus Community – read more The Power of Advocacy – read more Bolstering Diversity To Accelerate Research […]
MARCH 26 STATEMENT: Lupus Research Alliance Puts Plaquenil (Hydroxychloroquine) Shortage into Perspective for Lupus Community
March 26, 2020 The Lupus Research Alliance (LRA), the world’s leading research organization dedicated to lupus research, continues to watch rapidly changing developments regarding COVID-19 and is closely monitoring the policies and actions of the federal government, healthcare agencies, medical organizations and the pharmaceutical industry on behalf of people with lupus. Thrust into the spotlight […]
Study Shows Kidney Transplant Improves Lupus Nephritis Survival
January 21, 2019 A study just published in Annals of Internal Medicine showed that kidney transplantation reduced deaths due to lupus nephritis — kidney inflammation caused by lupus. Up to 60 percent of people with SLE are diagnosed with lupus nephritis, which can lead to significant illness and even death. According to the National Institute of Diabetes […]
Patients with Lupus Nephritis-Related Kidney Disease Are Living Longer
March 28, 2019 A new study published this March in Arthritis & Rheumatology found that deaths among patients with end-stage renal disease (ESRD) due to lupus nephritis (LN) fell significantly — by 32% —over the past two decades. The study took into account deaths from all causes, including deaths from cardiovascular disease (CVD) and infection. […]